Clinical Trial Update: PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update indicates that the Phase 1/2 study combining PTK787 with trastuzumab for HER2-overexpressing metastatic breast cancer has been termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• PTK787 (Vatalanib)

Snippet

Sponsor: Hoosier Cancer Research Network | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED